A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036
Phase 3
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Hodgkin's Lymphoma
Both
Non-Hodgkin's Lymphoma
Trial Information
A MULTI-CENTER LONG-TERM FOLLOW-UP STUDY OF PATIENTS WITH LOW-GRADE NON-HODGKIN'S LYMPHOMA PREVIOUSLY TREATED WITH IODINE I 131 TOSITUMOMAB IN STUDIES CP-97-011, CP-98-025, CP-99-032, or CP-99-036
Inclusion Criteria:
- Patients must have enrolled in one of the following Corixa sponsored clinical trials:
CP-97-011, CP-98-025, CP-99-032, or CP-99-036 and are >2 years post treatment with
Iodine I 131 Tositumomab.
- Patients must give written informed consent by signing an IRB/ethics committee
approved consent form prior to entry on this follow-up study.
Exclusion Criteria:
- Inability to meet above referenced inclusion criteria.
Type of Study:
Observational
Study Design:
N/A
Principal Investigator
GSK Clinical Trials, MD
Investigator Role:
Study Director
Investigator Affiliation:
GlaxoSmithKline
Authority:
United States: Food and Drug Administration
Study ID:
BEX104528
NCT ID:
NCT00240578
Start Date:
August 2003
Completion Date:
March 2016
Related Keywords:
- Non-Hodgkin's Lymphoma
- Low-grade lymphoma
- Iodine I 131 Tositumomab
- BEXXAR
- Long-Term Follow-up
- Lymphoma
- Lymphoma, Non-Hodgkin
Name | Location |
|---|---|
| GSK Clinical Trials Call Center | Aurora, Illinois 60506 |
| GSK Clinical Trials Call Center | Pittsfield, Massachusetts 01201 |
| GSK Clinical Trials Call Center | Albany, New York 12208 |
| GSK Clinical Trials Call Center | Des Moines, Iowa 50314 |
| GSK Clinical Trials Call Center | Ann Arbor, Michigan 48109 |
